Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Karuna Therapeutics Inc (NQ: KRTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Karuna Therapeutics Inc < Previous 1 2 3 Next > Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update February 22, 2024 From Karuna Therapeutics, Inc. Via Business Wire KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX February 14, 2024 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX) February 05, 2024 From Brodsky & Smith LLC Via GlobeNewswire Karuna Therapeutics Inc. (NASDAQ: KRTX) is a Leading Gainer in 12/22 Morning Trading December 22, 2023 Via Investor Brand Network BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX) January 30, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST) January 26, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST) January 22, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX) January 04, 2024 From Brodsky & Smith LLC Via GlobeNewswire KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX December 31, 2023 From Kahn Swick & Foti, LLC Via Business Wire Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals December 29, 2023 Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. Via MarketBeat BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX) December 26, 2023 From Brodsky & Smith LLC Via GlobeNewswire KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders December 22, 2023 From Halper Sadeh LLC Via Business Wire Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics December 22, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia December 14, 2023 From Karuna Therapeutics, Inc. Via Business Wire PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia November 29, 2023 From PureTech Health plc Via Business Wire Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia November 29, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia November 16, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates November 02, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress November 01, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics to Present at Upcoming Investor Conferences November 01, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023 October 19, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress October 04, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia September 28, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics to Present at Upcoming Investor Conferences August 30, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates August 03, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics Announces Leadership Appointments August 03, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023 July 20, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference May 30, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting May 22, 2023 From Karuna Therapeutics, Inc. Via Business Wire Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates May 04, 2023 From Karuna Therapeutics, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
